+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028

  • PDF Icon

    Report

  • 211 Pages
  • April 2021
  • Region: Global
  • Triton Market Research
  • ID: 5311019
Description Jump to:
According to this report, the global market for non-alcoholic steatohepatitis (NASH) biomarker is estimated to exhibit growth at a CAGR of 21.28% during the years 2021-2028.

The growing occurrence of NASH among people, paired with the increasing incidence rate of metabolic comorbidities, is boosting the reviewed market on a growth path. Besides, an increase in awareness regarding non-alcoholic fatty liver disease is opening new avenues for the NASH biomarker market over the projected period.



However, side-effects of NASH therapeutics, along with the unavailability of specialized diagnostic tests for NAFLD, are hampering the expansion of the global market on a large scale.

REGIONAL OUTLOOK

The global market includes the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions.
The Asia-Pacific is expected to observe the fastest growth rate in the non-alcoholic steatohepatitis biomarker market during the forecast period. The region's growth can be attributed to the advancements in the healthcare infrastructure, the surge in the prevalence of NASH, and improvement in economic conditions. Along with this, the growing healthcare awareness in emerging economies, including India and China, is expected to further influence the growth of the NASH biomarker market around the APAC region in the upcoming years.

COMPETITIVE OUTLOOK

The prominent companies engaged in the non-alcoholic steatohepatitis (NASH) biomarker include Allergan, Merck & Co, Novartis AG, Viking Therapeutics, Bristol Myers Squibb Company, Novo Nordisk, Genfit SA, Pfizer Inc, Madrigal Pharmaceuticals, Gilead Sciences Inc, AstraZeneca, Zydus Cadila, and Siemens Healthineers.
Allergan is engaged in developing, manufacturing, marketing, and distributing specialty, biosimilar, and over-the-country products. Its product portfolio includes cenicriviroc that blocks two chemokine receptors involved in inflammatory and fibrogenic pathways. This product's phase 3 AURORA plans to enroll a large number of patients suffering from NASH. Allergen has operations in numerous regions, such as Asia-Pacific, Europe, and Latin America, serving a wide consumer base. It is headquartered in Dublin, Ireland.
Frequently Asked Questions about the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market

What is the estimated value of the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market?

The Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market was estimated to be valued at $958.7 million in 2021.

What is the growth rate of the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market?

The growth rate of the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market is 21.2%, with an estimated value of $3700 million by 2028.

What is the forecasted size of the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market?

The Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market is estimated to be worth $3700 million by 2028.

Who are the key companies in the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market?

Key companies in the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market include Allergan, Astrazeneca, Bristol Myers Squibb Company, Genfit Sa, Gilead Sciences Inc, Madrigal Pharmaceuticals, Merck & Co, Novartis AG and Pfizer Inc.
Report AttributeDetails
No. of Pages211
PublishedApril 2021
Forecast Period2021 - 2028
Estimated Market Value ( USD ) in 2021 $ 958.7 million
Forecasted Market Value ( USD ) by 2028 $ 3700 million
Compound Annual Growth Rate21.2%
Regions CoveredGlobal

Table of Contents

1. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - Summary
2. Industry Outlook
2.1. Key Insights
2.1.1. Demand for NASH Biomarkers
2.1.2. Unmet Medical Needs
2.2. Impact of COVID-19 on Non-Alcoholic Steatohepatitis (NASH) Biomarker Market
2.3. Porter's Five Forces Analysis
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitute Products
2.3.3. Bargaining Power of Buyers
2.3.4. Bargaining Power of Suppliers
2.3.5. Competitive Rivalry
2.4. Market Attractiveness Index
2.5. Vendor Landscape
2.6. Key Market Strategies
2.6.1. Contracts & Partnerships
2.6.2. Business Expansions & Divestitures
2.6.3. Acquisitions & Mergers
2.6.4. New Product Launches
2.7. Market Drivers
2.7.1. Rising Prevalence of NASH
2.7.2. Increasing Incidence Rate of Metabolic Comorbidities
2.8. Market Restraints
2.8.1. Side-Effects of NASH Therapeutics
2.8.2. Unavailability of Specialized Diagnostic Test for Non-Alcoholic Fatty Liver Disease (Nafld)
2.9. Market Opportunities
2.9.1. Growth Opportunities in Developing Regions
2.9.2. Rise in Awareness Pertaining to Non-Alcoholic Fatty Liver Disease
3. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - by Type
3.1. Serum Biomarker
3.2. Hepatic Fibrosis Biomarker
3.3. Apoptosis Biomarker
3.4. Oxidative Stress Biomarker
3.5. Other Types
4. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - by Industry Verticals
4.1. Pharma & Cro Industry
4.2. Diagnostic Lab
4.3. Academic Research Key
4.4. Hospital
5. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - Regional Outlook
5.1. North America
5.1.1. Market by Type
5.1.2. Market by Industry Verticals
5.1.3. Country Analysis
5.1.3.1. United States
5.1.3.2. Canada
5.2. Europe
5.2.1. Market by Type
5.2.2. Market by Industry Verticals
5.2.3. Country Analysis
5.2.3.1. Germany
5.2.3.2. France
5.2.3.3. United Kingdom
5.2.3.4. Italy
5.2.3.5. Russia
5.2.3.6. Spain
5.2.3.7. Rest of Europe
5.3. Asia-Pacific
5.3.1. Market by Type
5.3.2. Market by Industry Verticals
5.3.3. Country Analysis
5.3.3.1. China
5.3.3.2. Japan
5.3.3.3. Australia & New Zealand
5.3.3.4. India
5.3.3.5. South Korea
5.3.3.6. Asean Countries
5.3.3.7. Rest of Asia-Pacific
5.4. Latin America
5.4.1. Market by Type
5.4.2. Market by Industry Verticals
5.4.3. Country Analysis
5.4.3.1. Mexico
5.4.3.2. Brazil
5.4.3.3. Rest of Latin America
5.5. Middle East and Africa
5.5.1. Market by Type
5.5.2. Market by Industry Verticals
5.5.3. Country Analysis
5.5.3.1. Saudi Arabia
5.5.3.2. United Arab Emirates
5.5.3.3. Turkey
5.5.3.4. South Africa
5.5.3.5. Rest of Middle East & Africa
6. Competitive Landscape
6.1. Allergan
6.2. Astrazeneca
6.3. Bristol Myers Squibb Company
6.4. Genfit Sa
6.5. Gilead Sciences Inc
6.6. Madrigal Pharmaceuticals
6.7. Merck & Co
6.8. Novartis AG
6.9. Novo Nordisk
6.10. Pfizer Inc
6.11. Siemens Healthineers
6.12. Viking Therapeutics
6.13. Zydus Cadila
7. Research Methodology & Scope
7.1. Research Scope & Deliverables
7.1.1. Objectives of Study
7.1.2. Scope of Study
7.2. Sources of Data
7.2.1. Primary Data Sources
7.2.2. Secondary Data Sources
7.3. Research Methodology
7.3.1. Evaluation of Proposed Market
7.3.2. Identification of Data Sources
7.3.3. Assessment of Market Determinants
7.3.4. Data Collection
7.3.5. Data Validation & Analysis
List of Tables
Table 1: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Regional Outlook, 2021-2028 (In $ Million)
Table 2: Vendor Landscape
Table 3: List of Contracts & Partnerships
Table 4: List of Business Expansions & Divestitures
Table 5: List of Acquisitions & Mergers
Table 6: List of New Product Launches
Table 7: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2021-2028 (In $ Million)
Table 8: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2021-2028 (In $ Million)
Table 9: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Regional Outlook, 2021-2028 (In $ Million)
Table 10: North America Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Country Outlook, 2021-2028 (In $ Million)
Table 11: North America Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2021-2028 (In $ Million)
Table 12: North America Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2021-2028 (In $ Million)
Table 13: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker, Country Outlook, 2021-2028 (In $ Million)
Table 14: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2021-2028 (In $ Million)
Table 15: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2021-2028 (In $ Million)
Table 16: Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Country Outlook, 2021-2028 (In $ Million)
Table 17: Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2021-2028 (In $ Million)
Table 18: Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2021-2028 (In $ Million)
Table 19: Latin America Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Country Outlook, 2021-2028 (In $ Million)
Table 20: Latin America Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2021-2028 (In $ Million)
Table 21: Latin America Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2021-2028 (In $ Million)
Table 22: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Country Outlook, 2021-2028 (In $ Million)
Table 23: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2021-2028 (In $ Million)
Table 24: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2021-2028 (In $ Million)
List of Figures
Figure 1: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 2: Porter's Five Forces Analysis
Figure 3: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2020 & 2028 (In %)
Figure 4: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Serum Biomarker, 2021-2028 (In $ Million)
Figure 5: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Hepatic Fibrosis Biomarker, 2021-2028 (In $ Million)
Figure 6: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Apoptosis Biomarker, 2021-2028 (In $ Million)
Figure 7: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Oxidative Stress Biomarker, 2021-2028 (In $ Million)
Figure 8: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Other Types, 2021-2028 (In $ Million)
Figure 9: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2020 & 2028 (In %)
Figure 10: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Pharma & Cro Industry, 2021-2028 (In $ Million)
Figure 11: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Diagnostic Lab, 2021-2028 (In $ Million)
Figure 12: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Academic Research Key, 2021-2028 (In $ Million)
Figure 13: Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Hospital, 2021-2028 (In $ Million)
Figure 14: United States Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 15: Canada Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 16: Germany Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 17: France Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 18: United Kingdom Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 19: Italy Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 20: Russia Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 21: Spain Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 22: Rest of Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 23: China Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 24: Japan Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 25: Australia & New Zealand Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 26: India Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 27: South Korea Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 28: Asean Countries Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 29: Rest of Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 30: Mexico Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 31: Brazil Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 32: Rest of Latin America Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 33: Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 34: United Arab Emirates Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 35: Turkey Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 36: South Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 37: Rest of Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergan
  • Astrazeneca
  • Bristol Myers Squibb Company
  • Genfit Sa
  • Gilead Sciences Inc
  • Madrigal Pharmaceuticals
  • Merck & Co
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc
  • Siemens Healthineers
  • Viking Therapeutics
  • Zydus Cadila

Methodology

Loading
LOADING...

Related Topics

Related Reports

Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size Outlook to 2028 - Growth Opportunities, Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Insights, Companies, Market share by Types, Applications, and Countries - Product Image

Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size Outlook to 2028 - Growth Opportunities, Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Insights, Companies, Market share by Types, Applications, and Countries

  • Report
  • 148 Pages
  • Global
From
NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value forecast, New Business Opportunities and Companies: Outlook by Type, Application, by End User and by Country, 2022-2030 - Product Image

NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value forecast, New Business Opportunities and Companies: Outlook by Type, Application, by End User and by Country, 2022-2030

  • Report
  • 142 Pages
  • Global
From
NASH Biomarkers Market Growth Opportunities to 2030 - NASH Biomarkers Market Size Outlook, Mega Trends, Potential Countries, Types, Applications, Companies, and Developments - Product Image

NASH Biomarkers Market Growth Opportunities to 2030 - NASH Biomarkers Market Size Outlook, Mega Trends, Potential Countries, Types, Applications, Companies, and Developments

  • Report
  • 170 Pages
  • Global
From
Global Non-alcoholic Steatohepatitis Biomarkers Market Forecast, 2022-2028 - Product Image

Global Non-alcoholic Steatohepatitis Biomarkers Market Forecast, 2022-2028

  • Report
  • 130 Pages
  • Global
From
Non-alcoholic Steatohepatitis Biomarkers Market Analysis by Type (Hepatic Fibrosis, Serum, Oxidative Stress, Apoptosis), by End User (Hospitals, Pharmaceutical & CRO Industry, Diagnostic Labs), and by Region - Forecast to 2029 - Product Image

Non-alcoholic Steatohepatitis Biomarkers Market Analysis by Type (Hepatic Fibrosis, Serum, Oxidative Stress, Apoptosis), by End User (Hospitals, Pharmaceutical & CRO Industry, Diagnostic Labs), and by Region - Forecast to 2029

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2023 Research and Markets. All Rights Reserved.